Editas Medicine, Inc.
EDIT
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Editas Medicine, Inc. is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies. As part of its product development and regulatory compliance process, the company conducts preclinical animal studies. These studies are a standard, and often required, component of the pathway to bring new human therapeutics to clinical trials. For example, the company's filings with the U.S. Securities and Exchange Commission reference animal studies performed in accordance with FDA Good Laboratory Practice regulations. Editas Medicine is listed by Cruelty Free Investors as a company that exploits animals through testing for its medical products.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.